Gujarat Inject (Kerala) approves Q2 and H1 standalone results to 30 Sep 2026
Gujarat Inject (Kerala) · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited standalone results for the quarter and half-year ended 30 September 2026 on 5 November 2026
- Half-year Total Income Rs. 1,827.43 lakhs, net profit Rs. 197.69 lakhs, basic EPS 0.13 as reported in the filing
- Auditor's emphasis of matter: trade receivables of Rs. 574.16 lakhs outstanding over one year with no ECL provision; management says recovery is possible
Why it's rated major development: the year-on-year change is 975% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On 05Th November, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other fundraise / allotment filings this fortnight
- Flywings Simulator Training Centre seeks approval for 29,87,760 warrants at ₹245
- Flywings Simulator Training Centre approves preferential issue of 29,87,760 warrants
- Rashi Peripherals Limited announces Board decisions and share issuance proposal
- Rashi Peripherals announces Board changes, share sale, and equity issuance plans
- Rashi Peripherals Limited approves several corporate actions and appointments
- Rashi Peripherals Limited announces Board Meeting outcomes dated Nov 5, 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.